Th1 and Th2 Cells: How Do They Exert Distinct Functions in Immune Responses and Influence Disease Progression?

I. How Do CD4+ T Cells Differentiate into Functionally Distinct Th1 and Th2 Cells?

CD4+ T cells, as the core regulators of the adaptive immune system, undergo a precisely regulated differentiation process. Naïve CD4+ T cells are activated upon recognizing the MHC class II-peptide complex on the surface of antigen-presenting cells via their T cell receptor, with co-stimulation from molecules like CD28, and initially differentiate into an intermediate state known as Th0 cells. Acting as a common precursor, the subsequent differentiation fate of Th0 cells depends on a complex interplay of multiple factors.

The nature of the antigen is a key determinant of the differentiation pathway. Intracellular pathogens, such as viruses and Mycobacterium tuberculosis, primarily promote differentiation towards the Th1 lineage by inducing macrophages to produce IL-12 and natural killer cells to produce IFN-γ. Conversely, extracellular pathogens like parasites and allergens drive Th2 cell differentiation by activating mast cells and NKT cells to produce IL-4. This selective differentiation has significant physiological importance, ensuring the immune system mounts the most effective response against different pathogen types.

II. What are the Key Signaling Pathways in Th1 vs. Th2 Cell Differentiation?

Th1 cell differentiation primarily relies on the IL-12/IFN-γ/STAT4/T-bet signaling axis. IL-12, secreted by antigen-presenting cells, binds to its receptor, activating the STAT4 transcription factor, which in turn induces T-bet expression. T-bet, the master regulator of Th1 differentiation, not only promotes sustained IFN-γ production but also suppresses GATA3 expression, thereby preventing Th2 differentiation. IFN-γ further reinforces this process through the STAT1 signaling pathway, creating a positive feedback loop.

In contrast, Th2 cell differentiation centers on the IL-4/STAT6/GATA3 signaling pathway. The initial IL-4 signal, potentially derived from activated mast cells, basophils, or NKT cells, activates STAT6, inducing GATA3 expression. GATA3, a key transcription factor for Th2 differentiation, directly regulates the expression of characteristic Th2 cytokines like IL-4, IL-5, and IL-13, while simultaneously inhibiting the T-bet-mediated Th1 differentiation program. Additionally, epithelial cytokines like thymic stromal lymphopoietin (TSLP) promote Th2 differentiation by enhancing GATA3 expression.

III. How Do the Effector Molecules and Immune Functions of Th1 and Th2 Cells Differ?

Th1 cells primarily secrete characteristic cytokines such as IFN-γ, IL-2, and TNF-α, orchestrating cell-mediated immune responses through these mediators. IFN-γ is the core effector molecule of Th1 cells, potently activating macrophages and enhancing their ability to phagocytose and kill intracellular pathogens. Furthermore, IFN-γ promotes B cells to produce opsonizing IgG antibody subclasses, effectively tagging pathogens for clearance by phagocytes. IL-2 drives the proliferation and differentiation of cytotoxic T lymphocytes (CTLs), enhancing their ability to kill virus-infected cells and tumor cells.

Th2 cells, conversely, coordinate humoral immunity and defense against parasites via cytokines like IL-4, IL-5, and IL-13. IL-4 is a key regulator of the Th2 response, not only promoting IgE class switching in B cells but also maintaining Th2 cell differentiation itself through an autocrine manner. IL-5 specifically regulates the generation, activation, and tissue infiltration of eosinophils, playing a central role in anti-parasite immunity and allergic inflammation. IL-13 primarily affects epithelial cells, inducing mucus secretion, goblet cell hyperplasia, and airway hyperresponsiveness, thereby modulating tissue barrier function.

IV. How Do Th1 and Th2 Cells Maintain Immune Balance Through Mutual Antagonism?

A sophisticated mutual regulatory relationship exists between Th1 and Th2 cells, and this balance is crucial for maintaining immune homeostasis. IFN-γ produced by Th1 cells can inhibit Th2 cell proliferation and function by interfering with GATA3 transcriptional activity via the STAT1 signaling pathway. Simultaneously, IFN-γ can also inhibit IL-4 signaling, reducing the production of Th2 cytokines. This suppression ensures that during responses to intracellular pathogens, the Th2 response does not become overactive and interfere with effective cell-mediated immunity.

Correspondingly, Th2 cells inhibit the Th1 response through factors like IL-4 and IL-10. IL-4 directly interferes with IFN-γ signaling and suppresses IL-12 receptor expression, thereby weakening Th1 differentiation signals. IL-10 indirectly inhibits Th1 cell activation by suppressing the production of IL-12 and the expression of co-stimulatory molecules by antigen-presenting cells. This mutually antagonistic balance mechanism prevents the excessive dominance of either subset and ensures optimal allocation of immune resources.

V. What Diseases Result from Th1/Th2 Imbalance?

Disruption of the Th1/Th2 balance is closely associated with the pathogenesis of various diseases. Overactive Th1 responses are commonly observed in organ-specific autoimmune diseases, such as type 1 diabetes, multiple sclerosis, and rheumatoid arthritis. In these conditions, Th1 cells, via the production of IFN-γ and TNF-α, activate macrophages and CTLs, leading to damage of self-tissues. IFN-γ promotes aberrant expression of MHC class II molecules, enhancing the presentation of self-antigens, while TNF-α directly mediates tissue inflammation and destruction.

Conversely, Th2 response dominance is associated with allergic diseases and certain systemic autoimmune diseases. In asthma, atopic dermatitis, and allergic rhinitis, Th2 cells promote IgE production via IL-4, recruit eosinophils via IL-5, and induce airway hyperresponsiveness and epithelial remodeling via IL-13. In systemic sclerosis and chronic graft-versus-host disease, Th2 cytokines like IL-4 and IL-13 promote fibroblast activation and collagen deposition, leading to tissue fibrosis.

VI. What are the Respective Advantages of Th1 and Th2 Cells in Anti-infective Immunity?

The immune response dominated by Th1 cells is particularly suited for combating intracellular pathogens. In Mycobacterium tuberculosis infection, Th1 cells activate macrophages via IFN-γ, promoting the production of nitric oxide and reactive oxygen species, thereby enhancing the ability to kill phagocytosed bacteria. In viral infections, Th1 cells promote CTL proliferation via IL-2 and enhance natural killer cell activity via IFN-γ, effectively clearing virus-infected cells.

Th2 immunity is more adept at fighting extracellular pathogens, particularly multicellular parasites. In helminth infections, Th2 cells induce goblet cell hyperplasia and mucus secretion via IL-4 and IL-13, promoting worm expulsion; activate eosinophils via IL-5, mediating direct attack on the parasites; and induce IgE production via IL-4, activating mast cells and basophils to release various effector molecules that attack the parasites.

VII. What is the Significance of Th1 and Th2 Cell Plasticity in Immune Regulation?

The traditional view held Th1 and Th2 cells as stable, terminally differentiated subsets, but recent research indicates they possess a degree of plasticity. Under specific microenvironmental signals, Th1 cells might acquire the ability to produce Th2 cytokines like IL-4, while Th2 cells might express T-bet and produce IFN-γ. This plasticity increases the adaptability of the immune system but can also contribute to the chronicity of diseases.

Epigenetic mechanisms play a key role in T helper cell plasticity. Changes in histone modifications and DNA methylation patterns can alter the accessibility of transcription factor binding sites, allowing cells to change their cytokine expression profile in response to new microenvironmental signals. Understanding the molecular basis of this plasticity is highly significant for developing new immune intervention strategies.

VIII. What are the Promising Therapeutic Strategies Targeting the Th1/Th2 Balance?

Modulating the Th1/Th2 balance has become an important strategy for treating various immune-mediated diseases. In allergic diseases, restoring normal immune balance can be attempted by blocking the IL-4 and IL-13 signaling pathways or using allergen-specific immunotherapy. In autoimmune diseases, biologics targeting IFN-γ and TNF-α have shown significant efficacy.

Emerging therapeutic directions include: developing small-molecule compounds that modulate the activity of specific transcription factors; using epigenetic drugs to reshape T helper cell differentiation programs; restoring immune balance through cell therapy involving the infusion of regulatory T cells; and using bispecific antibodies to precisely adjust the Th1/Th2 ratio. These innovative therapies hold promise for providing more effective and specific treatment options for immune-related disorders.

With advances in single-cell technologies and epigenomic analysis, our understanding of Th1 and Th2 cells continues to deepen. These studies not only reveal the complex regulatory networks of the immune system but also provide a new theoretical foundation and potential targets for the development of precision immunotherapy.